Krishnamurthy Nithya, Ravetch Ethan, Karim Subha, Safer Joshua D
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Surgery, Division of Breast Surgery, Montefiore Medical Center, Montefiore Breast Care Center, Bronx, NY, USA.
J Gen Intern Med. 2025 Sep 4. doi: 10.1007/s11606-025-09824-9.
Few consensus guidelines exist regarding screening mammography recommendations for transgender and gender diverse (TGD) individuals.
Our study aimed to assess the utilization of screening mammograms in a large cohort of TGD individuals at a single institution and the factors influencing mammogram uptake.
Retrospective cross-sectional study.
800 TGD individuals actively engaged in care at a transgender medicine and surgery urban center.
We conducted a retrospective analysis of a database of TGD patients (N = 4052) actively engaged in gender-affirming care in a specialized center for transgender health in a large urban healthcare system. We included all individuals who were age 40 or older at the time of data collection (N = 800) and conducted chart reviews on use of screening mammography and results.
Of the 800 TGD individuals over age 40, 532 were recorded male at birth, and 268 were recorded female at birth. Among those aged 50 and above, 136 out of 382 (36%) had a screening mammogram, whereas among those aged 40-49 years old, 72 out of 418 (17%) had a screening mammogram. Twenty-five percent (28/88) of those who underwent chest masculinization surgery had a screening mammogram, while 34.2% (94/275) of those who underwent chest feminizing surgery had a screening mammogram. Twenty-one out of the 208 (10%) of mammograms performed had a BI-RADS category greater than or equal to 3 or greater on diagnostic mammograms.
In our single-center large cohort of TGD individuals, we found a low percentage of screening mammography use. In those 50 and above, an age cohort with clear guidelines for screening, only 36% had any screening mammogram, and Hispanic ethnicity, chest masculinizing, and chest feminizing surgery were significant predictors for getting any screening mammograms. Our findings suggest the need for increased compliance with screening guidelines in TGD individuals, consistent with those for cisgender women.
关于为跨性别者和性别多样化(TGD)个体进行乳腺钼靶筛查的建议,几乎没有达成共识的指南。
我们的研究旨在评估在一家机构的一大群TGD个体中乳腺钼靶筛查的利用率以及影响钼靶检查接受率的因素。
回顾性横断面研究。
800名在一个城市跨性别医学与外科中心积极接受治疗的TGD个体。
我们对一个大型城市医疗系统中一家专门的跨性别健康中心积极接受性别确认治疗的TGD患者数据库(N = 4052)进行了回顾性分析。我们纳入了在数据收集时年龄在40岁及以上的所有个体(N = 800),并对乳腺钼靶筛查的使用情况和结果进行了病历审查。
在800名年龄超过40岁的TGD个体中,532名出生时被记录为男性,268名出生时被记录为女性。在50岁及以上的人群中,382人中有136人(36%)进行了乳腺钼靶筛查,而在40 - 49岁的人群中,418人中有72人(17%)进行了乳腺钼靶筛查。接受胸部男性化手术的人中有25%(28/88)进行了乳腺钼靶筛查,而接受胸部女性化手术的人中有34.2%(94/275)进行了乳腺钼靶筛查。在进行的208次钼靶检查中,有21次(10%)在诊断性钼靶检查中的BI-RADS类别大于或等于3级或更高。
在我们的单中心大型TGD个体队列中,我们发现乳腺钼靶筛查的使用率较低。在50岁及以上这个有明确筛查指南的年龄组中,只有36%的人进行了任何乳腺钼靶筛查,西班牙裔、胸部男性化手术和胸部女性化手术是进行任何乳腺钼靶筛查的重要预测因素。我们的研究结果表明,TGD个体需要提高对筛查指南的依从性,这与顺性别女性的情况一致。